The monoculture of cord-blood-derived CD34(+) cells by an automated, membrane-based dynamic perfusion system with a novel cytokine cocktail

Human leukocyte antigen (HLA)-matched cord blood (CB) transplantation is a procedure for the treatment of certain hematological malignancies, hemoglobinopathies, and autoimmune disorders. However, one of the challenges is to provide a sufficient number of T cell-depleted hematopoietic stem and progenitor cells. Currently, only 4%–5% of the CB units stored in CB banks contain enough CD34(+) cells for engrafting 70-kg patients. To support this clinical need, we have developed an automated expansion protocol for CB-derived CD34(+) cells in the Quantum system’s dynamic perfusion bioreactor using a novel cytokine cocktail comprised of stem cell factor (SCF), thrombopoietin (TPO), fms-like tyrosine kinase 3 ligand (Flt-3L), interleukin-3 (IL-3), IL-6, glial cell line-derived neurotrophic factor (GDNF), StemRegenin 1 (SR-1), and a fibronectin-stromal-cell-derived factor-1 (SDF-1)-coated membrane. In an 8-day expansion of a 2 × 10(6) positively selected CD34(+) cell inoculum from 3 donor lineages, the mean cell harvest and cell viability were 1.02 × 10(8) cells and 95.5%, respectively, and the mean frequency of the CD45(+)CD34(+) immunophenotype was 54.3%. The mean differentiated cell frequencies were 0.5% for lymphocytes, 15.8% for neutrophils, and 15.4% for platelets. These results demonstrate that the automated monoculture protocol can support the expansion of CD34(+) cells with minimal lymphocyte residual.